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Hippocampal Neurodegenerative
Pathology in Post-stroke Dementia
Compared to Other Dementias and
Aging Controls
Rufus O. Akinyemi 1, 2*, Louise M. Allan 2, Arthur Oakley 2 and Rajesh N. Kalaria 2*
1Neuroscience and Ageing Research Unit, Institute for Advanced Medical Research and Training, College of Medicine,
University of Ibadan, Oyo, Nigeria, 2Neurovascular Research Group, Institute of Neuroscience, Newcastle University,
Newcastle upon Tyne, United Kingdom
Neuroimaging evidence from older stroke survivors in Nigeria and Northeast England
showed medial temporal lobe atrophy (MTLA) to be independently associated with
post-stroke cognitive impairment and dementia. Given the hypothesis ascribing MTLA
to neurodegenerative processes, we assessed Alzheimer pathology in the hippocampal
formation and entorhinal cortex of autopsied brains from of post-stroke demented and
non-demented subjects in comparison with controls and other dementias. We quantified
markers of amyloid β (total Aβ, Aβ-40, Aβ-42, and soluble Aβ) and hyperphosphorylated
tau in the hippocampal formation and entorhinal cortex of 94 subjects consisting
of normal controls (n = 12), vascular dementia, VaD (17), post-stroke demented,
PSD (n = 15), and post-stroke non-demented, PSND (n = 23), Alzheimer’s disease,
AD (n = 14), and mixed AD and vascular dementia, AD_VAD (n = 13) using
immunohistochemical techniques. We found differential expression of amyloid and tau
across the disease groups, and across hippocampal sub-regions. Among amyloid
markers, the pattern of Aβ-42 immunoreactivity was similar to that of total Aβ. Tau
immunoreactivity showed highest expression in the AD and mixed AD and vascular
dementia, AD_VaD, which was higher than in control, post - stroke and VaD groups
(p < 0.05). APOE ε4 allele positivity was associated with higher expression of amyloid
and tau pathology in the subiculum and entorhinal cortex of post-stroke cases (p< 0.05).
Comparison between PSND and PSD revealed higher total Aβ immunoreactivity in
PSND compared to PSD in the CA1, subiculum and entorhinal cortex (p < 0.05)
but no differences between PSND and PSD in Aβ-42, Aβ-40, soluble Aβ or tau
immunoreactivities (p > 0.05). Correlation of MMSE and CAMCOG scores with AD
pathological measures showed lack of correlation with amyloid species although tau
immunoreactivity demonstrated correlation with memory scores (p < 0.05). Our findings
suggest hippocampal AD pathology does not necessarily differ between demented and
non-demented post-stroke subjects. The dissociation of cognitive performance with
hippocampal AD pathological burden suggests more dominant roles for non-Alzheimer
neurodegenerative and / or other non-neurodegenerative substrates for dementia
following stroke.
Keywords: Alzheimer’s disease, cerebrovascular disease, mixed dementia, post-stroke dementia, stroke, vascular
dementia
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INTRODUCTION
Stroke accounts for half of the global burden of neurological
disorders while remaining the most common cause of acquired
disability, and a common cause of cognitive impairment and
dementia (Kalaria et al., 2016; Writing Group Members et al.,
2016; GBD 2015 Neurological Disorders Collaborator Group,
2017). Magnetic resonance imaging studies in a cohort of older
African stroke survivors participating in the Cognitive Function
After STroke (CogFAST)—Nigeria Study showed that medial
temporal lobe atrophy (MTLA) was an independent predictor
of post-stroke cognitive impairment and dementia (Akinyemi
et al., 2014, 2015). These findings were in concordance with
previous findings of MTLA significantly predicting progression
to cognitive impairment, dementia and death in the longitudinal
CogFAST Newcastle Study (Firbank et al., 2007, 2012) while
pathological studies unmasked hippocampal neuronal atrophy
as an important neuropathological substrate of post-stroke
dementia (PSD) in the Newcastle cohort (Gemmell et al., 2012).
The link between cerebrovascular disease, neurodegeneration
and cognition has long been debated (de la Torre andMussivand,
1993; Kalaria et al., 1993b). Evidence for this link has been
provided by experimental models (Kalaria et al., 1993a; Kitaguchi
et al., 2009) and from epidemiological studies (Schneider et al.,
2004; Petrovitch et al., 2005). Accumulation of Alzheimer
pathology in primary vascular brain disorders occurs largely as
a result of shared mechanisms of neurovascular unit dysfunction
(Iadecola, 2004; Kalaria et al., 2012). Experimental evidence
from animal studies has shown that amyloid production may be
exacerbated by cerebral hypoxia/ischaemia (Kalaria et al., 1993a;
Whitehead et al., 2005).
In a large post-mortem study, Aho and colleagues using
immunohistochemistry found no significant increase in amyloid
load in subjects with cerebrovascular disease (CVD) compared
to controls although there was a trend of increased deposition
of Aβ-42 over Aβ-40 (Aho et al., 2006). In this context
a post-mortem study of aging controls and subjects with
vascular dementia (VaD), reported increased accumulation of
total guanidine HCl extractable Aβ-42 peptides (over Aβ-40) by
Enzyme Linked Immunosorbent Assay (ELISA) in the temporal
cortex in the oldest VaD subjects as well as in older aged controls
(Lewis et al., 2006) although these increases were not evident by
immunohistochemistry.
Cross-sectional studies examining the relationship of Aβ
with cognitive function have also yielded conflicting results.
Whereas, some studies have reported significant correlation
between metrics of AD pathology and cognitive performance
(Bennett et al., 2006; Mormino et al., 2009) others have reported
dissociation between Alzheimer pathological load and cognitive
status especially in subjects with presumed high cognitive reserve,
mixed pathologies or non-AD subjects (Mufson et al., 1999;
Aizenstein et al., 2008; Stern, 2009). Similarly, the morphological
variants and anatomical localization of the AD pathology
may be important. Neuritic plaques and neurofibrillary tangles
have stronger impact on cognition than diffuse plaques, and
pathologies in the neocortical region exert more influence than
those in the allocortical regions (Nelson et al., 2009, 2012).
The hippocampus plays a very strategic role in the
neurobiology of memory, being involved in the hierarchical
spread of amyloid and tau (neurofibrillary tangles) (Braak and
Braak, 1991; Thal et al., 2002b). Whereas, amyloid is deposited in
the hippocampus in late stages, tau deposition occurs quite early
within the hippocampal formation during their natural histories,
and both deposits appear to relate to the connections of the
hippocampal circuitry (Lace et al., 2009).
Given the hypothesis ascribing MTLA to neurodegenerative
processes (Henon et al., 1998; Cordoliani-Mackowiak et al., 2003;
Firbank et al., 2007), we investigated Alzheimer pathology in the
hippocampal formation and entorhinal cortex of brain tissues
obtained from the CogFAST (Cognitive Function after Stroke)
Newcastle post-stroke cohort. Our objective was to quantify the
presence of markers of amyloid pathology (total Aβ, Aβ-40, Aβ-
42, and soluble Aβ) and a marker of hyperphosphorylated tau
pathology in post-stroke subjects with and without dementia
compared to aging controls, Alzheimer’s disease (AD) and mixed
AD and vascular dementia (AD-VaD). We hypothesized that in
tandem with MTLA, hippocampal Alzheimer pathology would
be differentially expressed in demented and non-demented
stroke survivors in comparison with other dementias and aging
controls.
METHODS
Subjects
Ninety-four human post-mortem brains were retrieved from
the Newcastle Brain Tissue Resource (NBTR) at the Campus
for Ageing and Vitality, Newcastle University, UK. Table 1
provides details of the demographic, cognitive and pathologic
characteristics of the subjects. Post-stroke subjects in the
longitudinal CogFAST-Newcastle Study were classified based on
the performance at the last cognitive assessment before death.
They were classified as post-stroke non-demented (PSND) if
CAMCOG score was >80 and Clinical Dementia Rating (CDR)
was less than 1, but as post-stroke demented (PSD) if CAMCOG
score was<80 and CDR score was>1 (Allan et al., 2011). Control
subjects were historical subjects that had no significant evidence
of cognitive impairment upon scrutiny of their medical records
and whose post-mortem brain tissue was considered devoid
of sufficient vascular or degenerative pathologies beyond the
threshold for assigning a specific pathologic diagnosis (Kalaria
et al., 2004; Gemmell et al., 2012).
Autopsies were performed between 24 and 92 h after death
and brains were fixed for between 6 and 34 weeks. Cognitive
scores on the Mini-Mental State Examination (MMSE) and
Cambridge Cognitive Examination (CAMCOG) proximate to
death as well as APOE genotypes were retrieved from clinical
and research records of the subjects in the CogFAST-Newcastle
cohort. The CogFAST-Newcastle Study and ancillary studies had
ethical approval from the local Newcastle Ethical committees and
participants gave written consent for brain tissue donation. Use
of brain tissue was also approved by the local Ethical committees
(Newcastle upon Tyne Hospitals National Health Service Trust,
UK) and the committee of the NBTR.
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TABLE 1 | Characteristics of study subjects.
Variable Control PSND PSD VaD AD AD_VaD
Number of cases (N) 12 23 15 17 14 13
Age, years 79.1 ± 6.8 83.7 ± 3.9 87.3 ± 5.9 85.1 ± 6.4 83.5 ± 5.9 84.8 ± 5.7
Gender (M/F) 7/5 13/10 6/9 7/10 8/6 /7
MMSE score N/A 27.1 ± 1.6 17.5 ± 3.7* NCD NCD NCD
CAMCOG total score N/A 89.1 ± 5.1 63.6 ± 13.5* NCD NCD NCD
Braak Stage median (range) 2.0 (1–4) 2.0 (0–5) 3.0 (0–4) 2.0 (1–4) 5.5 (4–6) 5.0 (1–6)*
CERAD score Median (range) NPD 2.0 (0–2) 1.0 (0–3) 1.0 (0–2) 3.0 (3–3)* 3.0 (1–3)*
Thal Stage-median (range) NPD 3.0 (2–4) 1.0 (0–3)* 2.0 (0–3) 4.0 (3–4)* 4.0 (3–4)*
Vascular Score total-median (range) NPD 13.0 (7–16) 12.0 (7–18) 14.0 (12–18) NPD 12.0 (7–15)
Vascular Score-hippocampus Median
(range)
N/A 2.0 (1–3) 2.0 (1–3) N/A N/A N/A
ApoE Genotypes (%) N/A e3/3(43.7; e3/4,
2/4(50.0)
Others (6.3)
e3/3 (53.8); e3/4
(23.1)
e2/3 (16.7) Others (6.4)
N/A N/A N/A
Time from stroke to death (months) N/A 60.7 ± 47.4 59 ± 21.8 N/A N/A N/A
Previous Stroke (% of cases) N/A Yes (52.6), No (42.1),
Unknown (5. 3)
Yes (30.8), No (61.5),
Unknown (7.7)
N/A N/A N/A
Location of lesion (% cases) N/A Parietotemporal (17.4),
deep WM (13.0),
cerebellum (8.7%)
unknown (60.9)
Parietotemporal (35.7),
deep WM (21.4),
cerebellum (7.1),
unknown (35.7)
N/A N/A N/A
Side of Lesion (% cases) N/A Left (8.7), Right (21.7),
Both (26.1), None
(26.1), Unknown (17.4)
Left (35.7), Right (21.4),
Both (14.3), None
(21.4), Unknown (7.1)
N/A N/A N/A
Vascular territory N/A MCA (30.4%), PCA
(8.7), Unknown (60.9)
MCA (57.1),
Vertebrobasilar (7.1),
Unknown (35.7)
N/A N/A N/A
Values show mean ± SD unless otherwise indicated. Post-mortem delay between autopsy and fixation of tissue (hours) and Fixation length (weeks) ranged 24–92 h and 6–34 weeks,
respectively. There was no correlation between these variables and presence of pathology. *p < 0.001. AD, Alzheimer’s disease; AD_VaD, Mixed AD_VaD; PSND, MCA; Middle cerebral
artery; N/A, Not Applicable NCD, No Cognitive Data; NPD, No Pathological Data PCA, Posterior cerebral artery; PMD, Postmortem delay; PSD, Post-stroke demented; Post-stroke
non-demented; VaD, Vascular dementia.
Post-mortem reports were retrieved for all the cases used
in this study. Primary neuropathological diagnoses were made
from brain tissue sampled at several coronal levels (Perry and
Oakley, 1993) to check for pathological changes consistent with
AD, VaD and mixed AD_VaD in accordance with established
pathologic diagnostic criteria (Hyman and Trojanowski, 1997;
Kalaria et al., 2004), and following macroscopic and microscopic
post-mortem examination of the brain tissue. Haematoxylin
and Eosin was utilized as a standard stain for a general
neuropathologic structural evaluation of the brain, and for the
detection of infarcts and rarefactions. Gallyas and Bielschowsky’s
silver impregnation stains and AT8 immunohistochemistry were
used to evaluate “CERAD” neuritic plaques and neurofibrillary
tangles according to the methods of Braak (Braak and Braak,
1991; Mirra et al., 1991). In addition, vascular lesions (cortical
and sub-cortical infarcts, border-zone infarcts, strategic infarcts,
lacunar infarcts (<15mm), microinfarcts (<5mm) and mild,
moderate and severe cerebral amyloid angiopathy were recorded
(Kalaria et al., 2004). Final diagnoses were assigned during
monthly clinicopathologic consensus meetings. A final diagnosis
of VaD was made if there was clinical evidence of dementia
(DSM IV) and pathologic evidence of multiple or cystic infarcts,
lacunes, micro-infarcts, small vessel disease in the absence of
severe degenerative pathology (Braak Stage <III) (Kalaria et al.,
2004). Subjects were assigned mixed AD_VaD if there was
pathologic evidence of cerebrovascular disease in the presence of
significant AD pathology (Braak Stage V or VI) and moderate
to severe CERAD scores. A diagnosis of AD was assigned when
there was significant Alzheimer pathology-BraakV–VI,moderate
to severe CERAD score and absence of significant vascular
pathology.
APOE Genotyping
APOE genotyping was undertaken in the CogFAST cohort
only (PSND and PSD) as shown in Table 1 using restriction
enzyme isoform genotyping as previously described (Hixson and
Vernier, 1990; Rowan et al., 2005). In brief, ApoE restriction
isotyping used oligonucleotides to amplify apolipoprotein E gene
sequences containing amino acid positions 112 and 158. The
amplification products were digested with HhaI and subjected
to electrophoresis on polyacrylamide gels. Each of the isoforms
was distinguished by a unique combination of HhaI fragment
sizes that enabled unambiguous typing of all homozygotic and
heterozygotic combinations. HhaI cleaves at GCGC encoding
112arg (E4) and 158arg (E3, E4), but does not cut at GTGC
encoding 112cys (E2, E3) and 158cys (E2).
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Immunohistochemistry
Paraffin embedded brain tissue blocks taken from relevant
coronal levels of the Newcastle Brain Map (Perry and Oakley,
1993) and containing the hippocampal formation and entorhinal
cortex were cut into 10µm serial sections using a rotary
microtome. Sections were mounted on slides coated with
2% APES (3-aminopropyltrethoxysilane) solution in acetone,
and dried in a pre-heated oven at 600C for 30min. The
cut sections were then serially immunostained in duplicates
with primary antibodies to different amyloid-β species and
tau (Table 2). The sections were first de-paraffinized in two
sequential solutions of Xylene for 15min and then rehydrated
using decreasing concentrations of ethanol (100, 95, 70, and
50%) to deionized water. Antigen retrieval was performed for
Aß-immunolabeling using formic acid-pretreatment for 4 h and
for tau immunolabeling using heat in the form of microwaving
sections for 10min in a solution of 0.01M citrate buffer (PH
6.0). The buffer was brought to boil in the microwave, slides
were added, buffer was microwaved at 450W for 10min, and the
solution was then allowed to cool for 20min following which
slides were transferred to deionized water. Non-specific reaction
was quenched with 0.9% hydrogen peroxide (unless otherwise
stated.) in 5Mm Tris buffered Saline (TBS) solution (pH 7.6) for
15min in order to remove endogenous peroxidise. Non-specific
antigens were blocked using normal horse serum (anti-mouse
antibody: 4G8, NU-1 and AT8) and normal goat serum (anti-
rabbit antibody: T-40 and T-42 for 60min. The slides were then
incubated for 2 h at room temperature (AT8) or overnight at 40C
(4G8, T-40, T-42, and NU-1) with the primary antibody diluted
to specific concentration with buffer: total amyloid β (4G8, 1:
1000, Mouse monoclonal, Signet 9220-10), amyloid β-42 (T-42,
1: 5000, Rabbit polyclonal, gift; H. Mori, Japan), amyloid β-40
(T-40, 1: 5000, Rabbit polyclonal, gift; H. Mori, Japan), soluble
amyloid oligomer (NU-1, Mouse monoclonal, gift: C. Klein,
US) and antibody to hyperphosphorylated tau (AT8, 1: 1000,
Mouse monoclonal Autogen Bioclear). After washes in buffer,
biotinylated secondary antibody was applied to the sections with
the blocking serum for 30min, followed by the addition of
the streptavidin/biotinyl-horseradish peroxidase (HRP) complex
(SABC) for 30min to remove excess secondary antibody. Finally,
the slides were immersed in a 0.025% diaminobenzidine (DAB)
solution for a variable short period of time to visualize the
positive antibody reaction. Sections were then rinsed in water
and counterstained in haematoxylin as indicated. Sections were
then dehydrated back through graded alcohols, cleared in xylene
andmounted with glass coverslips using DPXmounting medium
(Sigma, UK). After each step, with the exception of the blocking
stage, sections were rinsed in buffer (TBS) three times for 5min
each. All immuno-histochemical protocols included a positive
control and a negative control for which the primary antibody
is omitted. All the antibodies used in the analysis have been
previously well characterized. We have published on use of these
antibodies as described in our previous publications (Chang
et al., 2003; Lewis et al., 2006; Ndung’u et al., 2012; Mukaetova-
Ladinska et al., 2015).
Microscopy and Image Analysis
Stained sections were examined and digitized using a Zeiss
Axioplan 2 research grade microscope coupled to an Infinity 2
camera. Magnification was set at X10 for the hippocampal sub-
regions CA1, CA2 and CA3, and X5 for the subiculum and
entorhinal cortex (EC). Five images were taken at random from
the CA1, CA3 and subiculum, 3 images fromCA2 and 4× 3 from
the EC from the pial surface to the white matter. Approximately
2,820 images were taken.
Images were analyzed using Image Pro Plus 6.3 (Media
Cybernetics, Silver Spring, MD, USA). The area of interest (AOI)
was delineated on-screen using the wand tool and the size of the
area selected was recorded. Histogram based analysis was used
to measure the number of pixels stained (“per area,” PA) and
intensity of stain (integrated optical density, IOD), as determined
by the operator. Background was excluded by highlighting only
the positive staining. To standardize themeasurements, the range
of stain intensity for each AOI was determined between 0 and
255 (where 0 = black and 255 = white, as set up for the Image
Pro Plus Histogram based analysis). Using the sum of each of the
three measures, further calculations were undertaken to generate
the metrics of immunostaining: Percent of the area of interest
positively stained, “Percent area (%PA)” = Per Area × 100;
Mean intensity of stain per pixel, “Integrated Optical Density
(IOD)”= 255 – (sum IOD/area). The mean % PA and IOD were
then calculated for each subject by computing averages from the
images taken from each hippocampal sub-region.
Statistics
Statistical analysis was carried out using the IBM SPSS
software (version 19.0). The Kolmogorov-Smirnov Test was
used to establish normality of data. Comparisons across
TABLE 2 | Summary of immunoperoxidase staining with DAB as chromogen.
Antibody Nature /Source Antigen retrieval Assay
buffer
Block Dilution Secondary
Antibody
SABC
4G8 Monoclonal/Mouse Concentrated formic acid TBS 1.5% NoHoS × 1 h 1:1000 O/N Anti-mouse Yes
T-42 Polyclonal/Rabbit Concentrated formic acid TBS 1.5% NoGoS × 1 h 1:5000 O/N Anti-rabbit Yes
T-40 Polyclonal/Rabbit Concentrated formic acid TBS 1.5% NoGoS × 1 h 1:5000 O/N Anti-rabbit Yes
NU-1 Monoclonal/Mouse Concentrated formic acid TBS – 1:3200 O/N Anti-mouse Yes
AT8 Monoclonal/Mouse Microwave/Citrate buffer TBS 1.5% NoHoS × 1 h 1: 1000 2 h Room Temperature Anti-mouse Yes
NoHoS, Normal horse serum; NoGoS, Normal goat serum; O/N, Overnight; SABC, avidin biotin complex; DAB, diaminobenzidine.
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groups of cases and across sub-regions were performed using
parametric tests (ANOVA for group means and Tukey post-hoc
analysis for between-group differences) and non-parametric
tests Kruskal–Wallis and Mann–Whitney U-tests) for non-
normally distributed dataset. The relationship among markers,
and with demographic, cognitive and pathological variables were
assessed using Pearson’s correlation coefficient (r) or Spearman’s
correlation (rho) as necessary depending on the normality of
the dataset. Appropriate power calculation was performed using
the G∗Power software (Faul et al., 2007) at significance level,
α-level = 0.05 and assuming a moderate effect size Cohen’s
d= 0.4.
RESULTS
Characteristics of Study Subjects
The demographic, cognitive and pathological characteristics of
the study participants [non-demented (PSND), demented (PSD)
subjects from the CogFAST-Newcastle study; Control, VaD, AD
andmixed AD-VaD groups] are shown in Table 1. There were no
significant differences in the age (p = 0.786), gender distribution
(p = 0.493), post-mortem delay (p = 0.902) and length of
fixation of tissues (p = 0.589) across the groups. However, the
PSND group had significantly higher scores on the cognitive
batteries MMSE and CAMCOG compared to the PSD group
(p < 0.05). Similarly, Braak stage, CERAD score and Thal stage
were significantly higher in the AD, AD-VaD groups compared
to the VaD and post-stroke groups (PSND and PSD) (p < 0.05).
Hippocampal vascular scores were similar among the PSND,
PSD, VaD and AD-VaD groups. The distribution of the ε3 and
ε4 alleles of APOE were not significantly different between the
PSND and PSD groups (Fisher’s exact test = 2.13; p = 0.249).
Given a total sample size of 94, a significance level, α = 0.05 and
assuming a moderate effect size Cohen’s d = 0.4, 6 sub-groups
and 5 degrees of freedom, the computed Power (1-β) = 0.8424
using the G∗Power software (Faul et al., 2007).
Quantification of Amyloid (Aβ) Burden
In quantifying amyloid burden both parenchymal as well
as vascular amyloid immunoreactivities were incorporated in
order to capture the total quantity of the different species
of amyloid detected within the defined area of interest as
previously performed (Lewis et al., 2006). Figure 1 illustrates the
immunostaining pattern with antibodies to various Aβ species in
serial sections across the CA1 sub-region of the hippocampus.
Immunolabeling of Total Aβ with 4G8 Antibody
Distribution of 4G8 antibody immunostaining dataset assessed
by Kolmogrov-Smirnov test showed non-normal distribution.
Spearman’s rank correlation analysis revealed no significant
associations between post-mortem delay, length of fixation
period and 4G8 immunoreactivity (IR) measures in the
hippocampal sub-regions and entorhinal cortex. Furthermore,
there was significant positive correlation between scores on the
semi-quantitative amyloid rating scales of CERAD, Thal, Braak
and tau stages with the metrics of 4G8 total IR in the entorhinal
FIGURE 1 | Illustrative images of amyloid pathology in the CA1 sub-region across different markers and across disease groups and aging controls. There is higher
expression of amyloid in the AD and AD_VaD groups compared with the VaD, PSD, and PSND and control groups. The level of amyloid immunoreactivity is similar
between 4G8 and T-42 but much lower in T-40 and NU-1.
Frontiers in Neuroscience | www.frontiersin.org 5 December 2017 | Volume 11 | Article 717
Akinyemi et al. Hippocampal Neurodegenerative Pathology in Post-Stroke Dementia
cortex, subiculum and CA1 sub-regions (Table 3) suggesting
good agreement between semi-quantitative and quantitative
measures of amyloid and tau quantification.
In the CA1 region, total Aβ IR varied significantly across
groups (p = 0.008, Kruskal-Wallis Test) (Figure 2). Between
group differences assessed with Mann–Whitney U-Test showed
that compared to the control group, total AβIR was significantly
higher in AD (p = 0.002), showed a trend with AD-VaD
(p = 0.064) and PSND (p = 0.076) but not significantly different
between PSD and VaD. In the CA2 and CA3 regions, there was
no significant variation across disease groups. In the subiculum,
there was significant variation across disease groups and controls
(p< 0.001, Kruskal–Wallis Test) with total IR being significantly
higher in the AD (p = 0.001), AD-VaD (p = 0.008) and PSND
(p = 0.015) groups but not significantly different between PSD
and VaD. In the entorhinal cortex, total Aβ IR similarly showed
significant variation across the sub-region (p < 0.001, Kruskal–
Wallis Test) with values significantly higher in AD (p = 0.022),
AD-VaD (p= 0.016) than in controls while PSD was significantly
lower than PSND (p = 0.019), AD-VaD (p = 0.002) and AD
(p= 0.002) (Figure 2).
Aβ-42 Immunohistochemistry with T-42 Antibody
In the CA1 region, Aβ-42 immunoreactivity varied significantly
across groups (p < 0.001, Kruskal-Wallis Test) (Figure 3).
Between group differences assessed with Mann–Whitney U-
Test showed that compared to the control group, T-42
immunoreactivity was significantly higher in AD (p = 0.002)
and AD-VaD (p = 0.005), but not significantly different
from VaD, PSND and PSD (Figure 3). In the CA2 region,
immunoreactivity varied across disease groups (p = 0.001,
Kruskal–Wallis Test) with the IR being significantly higher in
AD-VaD (p = 0.046) and VaD (p = 0.014) groups compared
to the control and PSD groups respectively (Figures 4B,
5). In the CA3 region, values revealed normal distribution
by Kolmogorov–Smirnov test of normality and ANOVA
showed significant variation of Aβ-42 immunoreactivity across
the regions (p < 0.001). Compared to the PSND group,
immunoreactivity was significantly higher in AD (p < 0.001)
and AD-VaD (p = 0.002) groups but not significantly different
from control PSD and VaD groups (Figure 3). In the subiculum,
Aβ-42 immunoreactivity varied significantly across groups
(p < 0.001) and was significantly higher in the AD (p = 0.001)
and AD-VaD (p = 0.008) groups compared to the control
and VaD groups respectively. However, the VaD groups did
not differ significantly from the PSND and PSD groups
respectively (Figures 4, 5). Similarly, Aβ-42 immunoreactivity
varied significantly across the entorhinal cortex (p < 0.001) and
was significantly higher in the AD (p = 0.001) and AD-VaD
(p = 0.001) groups but not different from the VaD, PSND and
PSD groups.
Aβ-40 Immunoreactivity with T-40 Antibody
Immunostaining and distribution of T-40 antibody across disease
groups varied significantly across the sub-regions (p = 0.001,
Kruskal–Wallis Test). In CA1, the IR in the control group was not
significantly different from that of PSND, PSD and, VaD but was
significantly lower than AD (p= 0.004) and AD-VaD (p= 0.010).
There was no difference between the PSND and PSD groups. In
TABLE 3 | Correlation Matrix of sub-regional total Aβ immunoreactivity, CERAD score, Thal stage, Braak stage and tau stage.
Spearmans rho CA1α CA2α CA3α SBα ECα Braakβ Tauβ Thalβ CERADβ
CA1α ρ 1.000
p
CA2α ρ 0.403** 1.000
p 0.000
CA3α ρ 0.444** 0.665** 1.000
p 0.000 0.000
SBα ρ 0.618** 0.169 0.243* 1.000
p 0.000 0.174 0.048
ECα ρ 0.490** 0.094 0.220* 0.758** 1.000
p 0.000 0.432 0.061 0.000
Braakβ ρ 0.420** 0.009 0.166 0.404** 0.429** 1.000
p 0.001 0.946 0.222 0.003 0.001
Tauβ ρ 0.316** 0.160 0.019 0.334** 0.474** 0.582** 1.000
p 0.008 0.194 0.878 0.008 0.000 0.000
Thalβ ρ 0.442** 0.223† 0.001 0.633** 0.653** 0.680** 0.685** 1.000
p 0.000 0.059 0.995 0.000 0.000 0.000 0.000
CERADβ ρ 0.341* 0.045 0.095 0.492** 0.524** 0.721** 0.597** 0.706** 1.000
p 0.11 0.749 0.492 0.000 0.000 0.000 0.000 0.000
α designates total Aβ (4G8) immunoreactivity in the CA1, CA2, CA3, subiculum (SB) and entorhinal cortex (EC) sub-regions of the hippocampus while β depicts CERAD score, Thal
stage, Braak stage and tau stage. Statistical significance designated by the following p-values: **p < 0.01; *p < 0.05;
†
p < 0.1. Abbreviations: CERAD, Consortium to Establish a
Registry for Alzheimer’s Disease.
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FIGURE 2 | Bar graphs showing the distribution of total Aβ IR across hippocampal sub-regions (A) CA1, (B) CA2, (C) CA3, (D) Subiculum, (E) Entorhinal cortex in
Controls, PSND, PSD, VaD, AD and AD_VaD. Bars show ± 2 SEM *Mann Whitney U-test was used to compare means of each group. *p < 0.05; + p < 0.1 (in
comparison with the control group). *(red) showed significant difference from PSD group. IR (immunoreactivity).
CA2, the control group IR was lower than AD, VaD and AD-
VaD although this did not attain statistical significance (p> 0.05).
However, VaD (p= 0.005) and AD-VaD (p= 0.006) groups were
significantly higher than the PSD group. The PSND group did not
differ from the PSD group (Figure 4). In the entorhinal cortex,
Aβ-40 IR was significantly higher in the AD and AD-VaD groups
compared to the control and PSD groups (p < 0.05, Kruska–
Wallis Test). There was no significant variation in the CA3 region
and subiculum.
We further explored the relationship of Aβ-42 and Aβ-40
based on the relative immuno-reactivities of T-42 and T-40 in
the CA1 sub-region. The ratio varied between 1.17 and 748.
39 and the mean value was least in the control group and
progressively increased in the PSND, PSD, VaD and AD groups
to attain a maximum value in the AD-VaD group (Data not
shown).
Soluble Aβ-Immunoreactivity with NU-1 Antibody
There were no significant differences in the percentage area
and total immunoreactivity of NU-1 across the disease groups
in the CA1, CA2, and CA3 regions (p > 0.05, Kruskal
Wallis Test). However, in the subiculum and entorhinal cortex,
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FIGURE 3 | Bar graphs showing the distribution of Aβ-42 IR across hippocampal sub-regions (A) CA1, (B) CA2, (C) CA34, (D) Subiculum, (E) Entorhinal cortex in
Controls, PSND, PSD, AD, VaD, and AD_VaD. Bars show ± 2 SEM *Mann Whitney U-test was used to compare means of each group. *p < 0.05; + p < 0.1 (in
comparison with control group). *(red) showed significant difference from PSND group. IR (immunoreactivity).
the immunoreactivity varied significantly (p < 0.05 Kruskal–
Wallis Test). Between group analysis showed significantly higher
immunoreactivity in the AD-VaD (p = 0.007 Mann–Whitney
U) group compared to the control group, and in the AD-VaD
(p = 0.008) and AD (p = 0.040) compared to the PSD group
(Figure 5). The PSND and PSD groups showed no significant
differences.
Hyperphosphorylated tau Immunoreactivity with AT8
Antibody
Figure 6A shows tau (AT8) immunoreactivity across disease
groups in the hippocampal subregion CA1 while Figure 6B
shows the quantification across different subregions. Across
disease groups, AT8 immunoreactivity was highest in AD
and AD_ VaD groups in comparison to each of the other
groups of PSND, PSD, VaD and Controls (p < 0.05). There
was slightly higher AT8 immunoreactivity in PSD compared
to the PSND group in the CA2 and CA3 sub-regions
(Figure 6B) although the difference did not attain statistical
significance.
Influence of APOE ε4 Genotype on Amyloid and tau
Accumulation in Post-Stroke Sub-Cohort
Eight out of 16 subjects with PSND (50%) were APO ε4 positive
compared to 3 out of 13 PSD cases (23.1%). Overall, 11 out
of 29 (37.9%) post-stroke subjects were APOE ε4 positive.
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FIGURE 4 | Bar graphs showing the distribution of Aβ-40 IR across hippocampal sub-regions (A) CA1, (B) CA2, (C) Entorbinal cortex in Controls, PSND, PSD, AD,
VaD and AD_VaD. Bars show ± 2 SEM *Mann Whitney U–test was used to compare means of each group. *p < 0.05; + p < 0.1 (in comparison with the control
group). *(red) showed significant difference from PSD group. lR (immunoreactivity).
Evaluation of the influence of APOE ε4 status on amyloid
and tau deposition in the post-stroke sub-cohort revealed
a statistically significant higher amyloid load in APOE ε4
positive post-stroke subjects compared to APOE ε4 negative
subjects in the subiculum and entorhinal cortex respectively
(p = 0.01) (Figure 7A). Presence of APOE ε4 also influenced tau
deposition (AT8 immunoreactivity) in the post-stroke cohort, the
immunoreactivity being significantly higher in APOE ε4 positive
subjects in the subiculum (Mann–Whitney U-Test, p = 0.042)
(Figure 7B).
Clinico-Pathological Correlations
We explored relationships between the various markers of
Alzheimer pathology used in this study and cognitive scores
of the post-stroke group utilizing Spearman correlation
analysis. Measures of general cognitive functioning (MMSE
and CAMCOG total) and functioning in the memory domain
(CAMCOG memory) were correlated with two measures
of Alzheimer pathological burden: Aβ-42 immunoreactivity
(being the predominant β-amyloid species deposited in the
hippocampus) and tau immunoreactivity measures in the
CA1, subiculum and entorhinal cortex: sub-regions which
demonstrated the most consistent patterns of variation
of immunoreactivity across the hippocampal formation.
Table 4 demonstrates significant correlation of only AT8
immunoreactivity in the subiculum with CAMCOG memory
(rho = −0.425, p = 0.024), whereas there was no significant
correlation with Aβ-42 immunoreactivity.
DISCUSSION
We hypothesized that Alzheimer pathology would be
differentially expressed in demented and non-demented
post-stroke subjects in comparison to normal aging controls and
other dementias. We found (1) amyloid beta deposition was not
remarkably different between PSD and PSND groups despite the
finding that MTLA was a significant feature in PSD subjects. (2)
As expected, concentrations of total amyloid beta and amyloid
β-42 were significantly greater in AD and mixed subjects
but low in post-stroke subjects consistent with insufficient
concentrations for a diagnosis of AD (3) an association between
APOE ε4 allele positivity and higher load of amyloid and tau
pathology in the subiculum and entorhinal cortex of post-stroke
cases (4) hyperphosphorylated tau immunoreactivity did not
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FIGURE 5 | Bar graph shows percentage area and immunoreactivity of soluble Aβ (IR) across the CA1 region (A,B) and Entorhinal cortex (C,D) respectively in Control
PSND, PSD, VaD, AD, and AD_VaD. Bars show ± 2 SEM *Mann Whitney U-test was used to compare means of each group. *p < 0.05 (in comparison with the
*control group and *PSD group). There were no significant differences across groups in the CA1, CA2, and CA3 regions (p > 0.05, Kruskal–Wallis Test).
differ significantly between PSND and PSD groups and (5) poor
correlation of cognitive measures with the burden of amyloid
and tau pathology in post-stroke subjects.
Amyloid Accumulation, Aging and
Cerebrovascular Disease
Consistently across all the markers of amyloid pathology,
we found evidence of increasing accumulation of amyloid in
controls, post-stroke groups, AD and AD_VaD in that order.
Our finding of amyloid accumulation in normal aging controls
concurs with the biological phenomenon of aging-associated
accumulation of amyloid that has been reported across species:
in drosophilia (Rogers et al., 2012), mice (Yamada et al., 2011),
non-human primates (Ndung’u et al., 2012) andman (Tomlinson
et al., 1968; Katzman et al., 1988; Bennett et al., 2006; Lewis
et al., 2006; Boyle et al., 2013b). This occurs as a result of
aging-related compromise of the neurovascular unit resulting in
increased production of amyloid and reduced clearance through
the perivascular space (Iadecola, 2004; Kalaria, 2009; Kalaria
et al., 2012). Amyloid accumulation in the post-stroke groups
mirrored that in the VaD group and was less than in the
AD and AD-VaD groups (Figures 2, 3) in consonance with
the findings of Lewis et al. (2006) showing enhancement of
amyloid accumulation in VaD possibly triggered by cerebral
hypoxia consequent to cerebral vascular disease (Lewis et al.,
2006; Kalaria et al., 2016). This is in tandem with previous
findings of enhanced accumulation of amyloid in animal models
of chronic cerebral hypoperfusion (Kalaria et al., 1993a; Yamada
et al., 2011) as well as increased Pittsburgh Compound B (PIB)
uptake in PSD subjects in a pilot study (Mok et al., 2010). In
addition, this suggests that beyond age-associated accumulation
of amyloid, cerebral vascular disorders including stroke do
exacerbate brain amyloid deposition as previously demonstrated
in brain tissue from hypertensive (Petrovitch et al., 2000) and
diabetic subjects (Luchsinger, 2010). Although Marchant et al.
failed to establish a direct relationship between CVD and Aβ
using PIB-PET approach in a cohort of non-demented elderly
subjects (Marchant et al., 2012), and further suggested that the
PIB-PET amyloid measures did not influence cognition, the
authors admitted that the limited statistical power of the study
may have failed to detect any existent interaction. Utilizing a
semi-quantitative approach, a neuropathological study of 484
post-mortem brains did not find a relationship between amyloid
deposition and cerebrovascular lesions (Aho et al., 2006). The
previous study by Lewis et al. (2006) and this current work
have utilized sensitive quantitative approaches to detect amyloid
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FIGURE 6 | (A) Hyperphosphorylated tau (AT8) immunoreactivities showing neuropil threads, pretangles and tangles in hippocampal sub-region CAl. AT8
immunoreactivity is relatively higher in AD and AD_VaD compared to other groups. (B) Bar graph showing the distribution of AT8 IR across hippocampal sub-region.
(a) CA1, (b) CA2, (c) CA3, (d) Subiculum (e) Entorhinal cortex in Controls. PSND. PSD. AD. VaD and AD_ VaD. Bars show ± 2 SEM *Mann Whitney U-test was used
to compare means of each group. *p < 0.05; (in comparison with the control group). *(red) showed significant difference from PSND group.
load. Besides, findings from studies in non-demented elderly
subjects may not necessarily simulate those in demented subjects
with significant CVD as the mechanisms that produce cognitive
decline and dementia may differ in different clinicopathological
scenarios (Kalaria, 2012a,b).
Although the main Aβ variants detected in the human brain
are Aβ1–40 and Aβ1–42, a significant proportion consists also
of N-terminal truncated species (Aβn-40/42 where n = 2 to 11)
of which pyroglutamate-modified Aβ peptides are predominant
components. Most N-truncated Aβ are considered to be the
degradation products of full-length Aβ although Aβ11–40/42
may be generated intracellularly directly from APP by BACE
proteolysis occurring in trans-Golgi network (Perez-Garmendia
et al., 2014). AβN3(pE), Aβ peptide bearing amino-terminal
pyroglutamate at position 3, has been shown to be a major N-
truncated/modified constituent of intracellular, extracellular and
vascular Aβ deposits in AD brain tissue (Saido et al., 1995)
which progressively accumulates in the brain and could predate
the development of AD symptoms. These truncated species are
believed to constitute a potential seeding specie in the formation
of pathological amyloid aggregates (Saido et al., 1995; Perez-
Garmendia et al., 2014) Although we did not specifically assay
for these pyroglutamate-modified Aβ peptides, they may have
contributed to the intraneuronal and vascular amyloid which was
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FIGURE 7 | (A) Box Plots showing the influence of Apo E ε4 on total amyloid deposition across hippocampal sub-regions (a) CA1, (b) CA2, (c) CA3, (d) Subicuhun,
and [e] Emorlrinal conex in the post-stroke sub-cohort Mann–Whitney U-test was used to compare the mean 4G8 total immunoreactivity between the Apo E ε4
positive and negative groups respectively. *p < 0.05. (B) Box Plot showing the influence of Apo E ε4 on total tau (AT8) deposition across hippocampal sub-regions (a)
CA1 (b) CA2 (c) CA3 (d) Subiculum and (e) Entorhinol cortex in the post-stroke sub-cohort. Mann Whitney U-test was used to compare mean AT8 total
immunoreactivity between the Apo E ε4 positive and negative groups respectively. *p < 0.05.
detected by the immunolabeling of total Aß (4G8) in the current
study.
Sub-Regional Variation in Hippocampal
Amyloid Accumulation
Across the sub-regions of the hippocampal formation and
entorhinal cortex, amyloid deposition was significantly higher
in the CA1, subiculum and entorhinal cortex compared to the
CA2 and CA3 regions respectively. This differential pattern may
be related to the spatial localization and role of these regions
in the hippocampal circuitry (Lavenex and Banta Lavenex,
2013), differential susceptibility of these sub-regions to different
pathologies (Small et al., 2011) or the temporal evolution and
hierarchical progression of cerebral amyloidosis (Thal et al.,
2006).
The entorhinal cortex has been described as the gateway into
the hippocampal formation whereas the subiculum and CA1
regions constitute the outflow stations (Goldman-Rakic et al.,
1984; Suzuki and Amaral, 2004). Alzheimer pathology tends to
spread along the hippocampal circuitry (Thal et al., 2002a; Lace
et al., 2009) and this may explain the differential susceptibility
and high β-amyloid load in these sub-regions. Besides, in the
hierarchical evolution and natural history of amyloid and tau
pathologies, these sub-regions are affected earlier in the disease
course, compared to other regions such as CA2 and CA3 (Thal
et al., 2002b; Lace et al., 2009). The later effect in the CA2 region,
in particular may reflect the natural course of disease or the
existence of some underlying protective mechanisms operating
in the early stages of disease and only giving way in the advanced
stage of the disease (Caruana et al., 2012).
The finding of a relatively higher ratio of Aβ-42 compared to
Aβ-40 which further increases with the degree of accumulation
of AD pathology is in concordance with previous findings (Aho
et al., 2006; Selkoe, 2008) demonstrating the predominance of
Aβ-42 over Aβ-40 in brain parenchymal amyloid deposits. We
have also previously demonstrated a preponderance of Aβ (42)
over Aβ-40 in parenchymal and vascular amyloid deposits in
non-human primates including squirrel, rhesus monkeys and
aging baboons (Ndung’u et al., 2012).
Differential Amyloid and tau Deposition
between PSND and PSD
Largely, there were no significant differences in the quantity
of amyloid and tau deposited across hippocampal regions and
markers in PSND compared to PSD groups. This suggests age-
related deposition of amyloid and tau in post-stroke survivors.
However, total Aβ immunoreactivity was unexpectedly higher
in the entorhinal cortex of PSND than PSD. Though not
statistically significant, a similar pattern was observed with
Aβ-42 in the subiculum, Aβ-40 in the entorhinal cortex, and
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TABLE 4 | Correlation matrix showing association of neuropathologic measures of amyloid and tau pathology with cognitive scores in selected hippocampal sub-regions
and entorhinal cortex.
Spearman’s rho CAMCOG memory CAMCOG total MMSE CA1α SBα ECα CA1β SBβ ECβ
CAM_memory ρ 1.000
p .
CAMCOG score ρ 0.814** 1.000
p 0.000 .
MMSE ρ 0.790** 0.951** 1.000
p 0.000 0.000 .
CA1α ρ −0.077 0.029 0.053 1.000
p 0.657 0.857 0.754 .
SBα ρ −0.419* −0.189 −0.047 0.793** 1.000
p 0.024 0.301 0.807 0.000 .
ECα −0.308 −0.064 −0.031 0.785** 0.686** 1.000
p 0.091 0.720 0.869 0.000 0.000 .
CA1β ρ −0.046 0.109 0.054 0.656** 0.493** 0.567** 1.000
p 0.792 0.513 0.759 0.000 0.000 .000 .
SBβ ρ −0.080 0.120 0.090 0.634** 0.563** 0.557** 0.779** 1.000
p 0.646 0.471 0.609 0.000 0.000 0.000 0.000 .
ECβ ρ −0.033 0.087 0.082 0.566** 0.457** 0.557** 0.566** 0.671** 1.000
p 0.849 0.606 0.641 0.000 0.000 0.000 0.000 0.000 .
soluble Aβ in the CA1 sub-region. This suggests that diffuse
early amyloid accumulation in post-stroke subjects alone does
not explain why some stroke survivors become demented while
others remain cognitively intact. Cognitively normal elderly
subjects with huge quantities of amyloid pathology but preserved
cognitive functioning have been described in the literature
(Bennett et al., 2006; Chetelat et al., 2010). It may also imply
that amyloid needs the synergy of other pathologies including
tau pathology, vascular lesions, brain atrophy, white matter
pathology, MTLA in order to produce significant cognitive
decline and dementia (Mormino et al., 2009). In a PIB-PET
study of elderly subjects-normal, mild cognitive impairment
(MCI) and AD, the investigators found that whereas amyloid
load (PIB index) and hippocampal atrophy both predicted loss
of episodic memory, amyloid deposition alone in the absence
of hippocampal atrophy failed to predict episodic memory loss
(Mormino et al., 2009). In addition, a recent study by Wong
et al. (2016), found that amyloid retention measured by 11C-
PiB PET showed no association with cognitive impairment and
clusters of neuropsychiatric symptoms suggesting that other
plausible biological pathways could be advanced to explain
the development and progression of cognitive impairment
and neuropsychiatric symptoms following stroke (Wong et al.,
2016). A complementary study of our current cohort (Gemmell
et al., 2012) found that whereas pyramidal neuronal volume
was preserved in the CA regions and entorhinal cortex of
the control and PSND groups, subjects in all the demented
groups (including PSD) had significant atrophy of these neurons.
This would, therefore, suggest that high amyloid load in the
PSND group was insufficient to produce dementia because of
preserved neuronal volume. This, indeed, may be a signature
of brain/cognitive reserve, preserved synaptic integrity or some
other compensatory mechanisms (Stern, 2009; Boyle et al.,
2013a).
The observation of similarity between amyloid load in the
PSD compared to the control group could imply that given
similar quantities of amyloid pathology with respect to the
controls, the PSD group was demented possibly because of the
presence of additional cerebrovascular lesions which lowered
the pathological threshold (Snowdon et al., 1997; Esiri et al.,
1999); the presence of neuronal atrophy (Gemmell et al., 2012) or
the slightly higher and more advanced hyperphosphorylated tau
pathology in the CA2 and CA3 sub-regions of the PSD group. A
recent study in which total and phosphorylated tau proteins were
quantified in the frontal and temporal cortices of subjects with
vascular dementia found a selective loss of total tau protein in
VaD compared with controls and AD, whereas phosphorylated
tau levels were similar to controls in VaD in both regions, but
they were increased in the temporal lobes of patients with AD
(Mukaetova-Ladinska et al., 2015). These results demonstrated
that breaches of microvascular or microstructural tissue integrity
subsequent to ischemic injury in older age may modify tau
protein metabolism or phosphorylation and have effects on the
burden of neurofibrillary pathology (Mukaetova-Ladinska et al.,
2015).
APOE ε4 Genotype and Accumulation of
Amyloid and tau Pathologies
Further analysis of the post-stroke cohort suggested that the
presence of the APOE ε4 allele was responsible for driving
amyloid and tau accumulation in those who possessed the allele
(which was present in 50%) of the PSND subjects. Despite the
limited size of the sub-cohort, the amyloid load was significantly
higher in the PSND group than the PSD group. APOE ε4
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has been associated with accumulation of amyloid and/or tau
pathology (Nagy et al., 1995; Saito et al., 2002) in AD but the
relationship with post-stroke dementia has been conflicting and
less well defined. Previous studies in the Newcastle cohort failed
to establish a relationship between APOE ε4 with post-stroke
cognitive impairment at 3 months after the stroke (Rowan et al.,
2005) but predicted decline at 1-year follow up (Ballard et al.,
2004). Furthermore, these results are in concordance with a
previous study examining the genetic associations of vascular
dementia subtypes in which an association was found between
APOE-ε4 allele andmixed dementia, stroke-related dementia and
subcortical ischemic vascular dementia (SIVD) as well as higher
Aβ-(42) levels (Jones et al., 2011). Other studies had also reported
both positive (Packard et al., 2007; Liu et al., 2012) and negative
associations (Gdovinova et al., 2006) although these were largely
clinical studies. It is plausible that the APOE ε4 allele might have
contributed to the higher quantity of amyloid in subregions of the
PSND group compared to the PSD group, but further research is
required to explore this relationship further.
Correlation of Cognitive Scores with AD
Pathology
In the post-stroke cohort with available cognitive scores, very
limited correlation of tau pathology with CAMCOG memory
score was established. In this cohort, there was dissociation of
cognitive performance and hippocampal Alzheimer pathologic
burden. The implication of this may be that AD pathology
probably does not contribute very strongly to the substrates of
dementia after a stroke event as previously hypothesized (Henon
et al., 1997). And if there was any contribution at all, tau
pathology probably contributed more than amyloid pathology.
Recent reports also suggest that MTLA which had hitherto been
widely ascribed to AD pathology, may have a vascular basis
(Bastos-Leite et al., 2007; O’Sullivan et al., 2008). The lack of
association may also be due to the presence of other pathologies
such as synucleinopathies, (the determination of which is beyond
the scope of the current study), presence of robust cognitive
reserve and other lifestyle and psychosocial factors might also
offer reasons for the dissociation between clinical and cognitive
measures in the current study. Our study had limitations.
We did not quantify specific isoforms of phosphorylated tau
protein (R3 or R4) in our cohort as this could yield different
amounts in the different subgroups. Alternative techniques
including neurochemical approaches such as ELISA could have
also be employed to further substantiate the findings from this
current study and the potential existence of familywise Type
1 error associated with multiple pairwise comparisons is also
acknowledged.
In conclusion, we did not find quantitative AD pathological
markers sufficient to separate the non-demented post-stroke
from demented post-stroke subjects. Thus, hippocampal AD-
pathological mechanisms do not separate non-demented from
demented stroke subjects. Neocortical Alzheimer pathology,
other non-Alzheimer neurodegenerative pathologies as well as
other non-neurodegenerative mechanisms such as vascular and
inflammatory/immune mechanisms require further research in
order to fully determine the precise pathological substrates of
dementia following stroke.
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